RecruitingNot Applicable

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

United States600 participantsStarted 2024-09-02

Plain-language summary

For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (SNPs) on the wild-type Huntington (wtHTT) and mutant Huntington (mHTT) alleles.

Who can participate

Age range25 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Have signed the Informed Consent Form (ICF) * Aged 25 to 60 years, inclusive, at the time of signing the ICF * Confirmation of Huntington Disease (HD) gene expansion mutation carrier status * Confirmation of Total Functional Capacity (TFC) ≥9 and Total Motor Score (TMS) \>6 within 12 months prior to signing the ICF * Ability to tolerate blood draws Exclusion Criteria: * None

What they're measuring

Frequencies of Selected Single Nucleotide Polymorphism (SNP) Alleles in Phase With the mHTT and wtHTT Alleles

Timeframe: Day 1

Trial details

NCT IDNCT06667414

SponsorHoffmann-La Roche

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-02-28

Contact for this trial

Reference Study ID Number: WE45491 https://forpatients.roche.com/

888-662-6728 (U.S. Only) global-roche-genentech-trials@gene.com

View on ClinicalTrials.gov More Huntington Disease trials